Physician profile
Jorge E Mendia
NPI 1982609178
$1,494.57
in general payments reported to CMS, 2019-2025
22 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $120 · 2021: $210 · 2022: $193 · 2023: $295 · 2024: $88.47 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $711.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $431.79 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $190.65 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $166.92 | 2022-2025 | |
| Coopersurgical, INC. | $87.37 | 2020-2025 | Endosee, Paragard T 380a |
| Pfizer INC. | $68.69 | 2022-2023 | |
| Hologic Sales and Service, LLC | $64.63 | 2022-2025 | Thinprep 2000 Processor, Aptima, Novasure |
| Biogen, INC. | $59.41 | 2025 | Zurzuvae |
| Myovant Sciences INC. | $52.59 | 2022 | |
| Millicent US INC | $46.85 | 2025 | Intrarosa, Femlyv |
| Sumitomo Pharma America, INC. | $46.84 | 2023-2025 | Gemtesa, Myfembree |
| Avion Pharmaceuticals | $39.46 | 2020-2021 | |
| Astellas Pharma US INC | $34.72 | 2024 | Veozah |
| Roche Diagnostics Corporation | $32.97 | 2019 | |
| Daiichi Sankyo INC. | $31.59 | 2019 | |
| Exeltis, USA INC. | $27.55 | 2023-2024 | Slynd |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $22.70 | 2023 | |
| Allergan, INC. | $20.00 | 2019 | |
| Avanos Medical | $16.83 | 2019 | |
| Organon LLC | $16.02 | 2023 | Nexplanon |
| Smith+Nephew, INC. | $15.35 | 2019 | |
| Merck Sharp & Dohme LLC | $14.19 | 2019 | |
| Channel Medsystems, INC. | $7.45 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Mendia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.